Loading...
XSHE
300181
Market cap1.65bUSD
Dec 05, Last price  
17.04CNY
1D
0.12%
1Q
-6.06%
Jan 2017
86.64%
IPO
320.20%
Name

Zhejiang Jolly Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300181 chart
P/E
23.04
P/S
4.54
EPS
0.74
Div Yield, %
2.64%
Shrs. gr., 5y
2.71%
Rev. gr., 5y
23.12%
Revenues
2.58b
+32.71%
126,585,142164,902,489215,349,830262,655,252279,327,509343,758,925419,415,230514,926,219670,857,129840,037,943793,911,691730,262,647911,163,9751,090,878,1691,457,396,0661,805,155,3651,942,492,9902,577,878,166
Net income
508m
+32.60%
13,894,15316,642,66031,584,33841,476,73050,927,86662,002,51380,997,527103,184,20384,772,99172,020,42545,140,28220,751,76925,592,84288,801,777179,408,091273,006,652382,936,093507,771,934
CFO
297m
+2.98%
16,047,61331,157,75743,892,65664,780,15013,654,67230,509,25729,503,76713,695,17097,128,28958,304,4566,506,36478,284,593128,942,614279,691,036251,798,511318,591,105288,461,038297,047,240
Dividend
May 22, 20240.45 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Jolly Pharmaceutical Co., Ltd. engages in the research, production, and marketing of Chinese medicinal products in China and internationally. The company offers Wuling capsule that is used to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kidney, or neurasthenia. It also provides Lingze tablet, which is used to treat frequent urination, dysuria, weak steam of urine, endless urine, and soreness and weakness of waist and knees caused by benign prostatic hyperplasia, kidney deficiency, and blood stasis; and Bailing tablet that is used as the adjuvant therapy to treat cough, asthma, back pain, and chronic bronchitis, which are caused by the deficiency of lungs and kidney. In addition, the company offers Linglianhua particles for the treatment of symptoms, including sweating, insomnia, dysphoria, heart palpitations, dreaminess, giddy tinnitus, lassitude in loin and legs, dry stool, and abnormal furred tongue, as well as weak pulse caused by perimenopausal syndrome, or disharmony of heart and kidney. Further, it provides azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside injections. Additionally, the company offers materials, such as cordyceps cephalosporium, fermented cordyceps, and Wuling powders. It also invests and participates in the medical services of Deqing No.3 People's Hospital. The company was formerly known as Zhejiang Jolly Pharmaceutical Health Products Co., LTD. and changed its name to Zhejiang Jolly Pharmaceutical Co., Ltd. in 1998. Zhejiang Jolly Pharmaceutical Co., Ltd. was founded in 2000 and is based in Huzhou, China.
IPO date
Feb 22, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT